Phage Therapy Explored for Bioreactor Control
Researchers are exploring industrial phage therapy as a precision tool for managing microbial contamination in large-scale bioreactors, according to a recent podcast. The strategy uses bacteriophages to selectively eliminate contaminants without requiring broad-spectrum chemical agents. This targeted approach could reduce batch losses and costly downtime in GMP manufacturing environments by allowing for a more rapid and less disruptive response to contamination events.
- The economic impact of microbial contamination is substantial, with a single failed production lot in a 2000L bioreactor potentially costing up to USD 1 million, and a month-long production stoppage for a blockbuster drug leading to lost revenues of up to USD 1 billion. Investigations into contamination events can add costs of around USD 20,000, while facility and equipment sanitization can reach up to USD 100,000. - Historically, bacteriophage contamination has been a significant issue in industrial fermentation, such as in acetone-butanol production, where it could lead to complete fermentation failure and lysis of the majority of cells within hours. In the dairy industry, phages were first identified as a cause of fermentation failure in products like yogurt and cheese in 1935. - A key challenge in applying phage therapy is the high specificity of phages to their bacterial hosts, which means a single phage type cannot treat all strains of a contaminating bacterium. This necessitates the use of "phage cocktails," or mixtures of different phages, to broaden the spectrum of activity and help prevent the development of phage-resistant bacteria. - The regulatory landscape for using phages in manufacturing is still evolving. In Europe, new harmonized quality criteria for phage therapy medicinal products were implemented in the European Pharmacopoeia in January 2025. In the U.S., phages are regulated as biological products by the FDA's Center for Biologics Evaluation and Research. - Companies like Intralytix are already marketing EPA-approved and FDA-cleared bacteriophage products for controlling pathogens like *Listeria*, *E. coli*, and *Salmonella* in food processing environments. Other companies actively developing industrial phage applications include Phage Consultants and various firms focused on phage-mediated biocontrol. - A significant hurdle for scaling up phage production is the cost and complexity associated with adapting and sterilizing conventional bioreactors. The development of phage-resistant bacterial mutants is also a primary concern that can lead to treatment failure. - The application of AI and machine learning is an emerging trend in this field, with startups like PhageAI and Obulytix using these technologies to accelerate the discovery, development, and optimization of phages and phage-derived enzymes. - Beyond bioreactors, phage therapy is being explored for soil remediation, biofuel production systems, and controlling biofilms on surfaces like water filtration membranes. For instance, phage cocktails have been shown to recover ethanol yields in fermentations contaminated with *Lactobacillus fermentum*.
